ω-3酸乙酯(Trygg Pharma AS)(Omega-3-acid ethyl esters(Trygg Pharma AS)) - 药物靶点：Lipid x Triglyceride_在研适应症：高脂血症，I型高脂蛋白血症，高甘油三酯血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lotriga Granular、Omega-3 fatty acid ethyl esters、OMEGA-3-ACID ETHYL ESTERS

+ [18]

靶点

Lipid x Triglyceride

作用机制

脂质调节剂、甘油三酯调节剂

治疗领域

遗传病与畸形内分泌与代谢疾病其他疾病+ [2]

在研适应症

高脂血症I型高脂蛋白血症高甘油三酯血症+ [2]

非在研适应症

急性心肌梗塞颈动脉狭窄心源性猝死+ [1]

原研机构

Trygg Pharma AS

在研机构

BASF Corp.Pronova BioPharma ASAViatris Pty Ltd.

+ [2]

非在研机构

Pronova Biopharma Norge AS

雅培贸易（上海）有限公司Osmotica Pharmaceutical US LLC

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2004-11-10),

高甘油三酯血症

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构

分子式C46H70O4

InChIKeyDTMGIJFHGGCSLO-FIAQIACWSA-N

CAS号861006-80-6

关联

373

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的临床试验

ChiCTR2400084087 / Suspended临床1期IIT

Pre IVF/ICSI intake Omega 3 Fatty Acid in PCOS patients:A multicenter, randomized, double-blind, placebo-controlled clinical trial

开始日期2025-06-01

申办/合作机构-

NCT06434948 / Not yet recruiting临床2期IIT

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery: a Prospective, Randomized, Controlled Trial

The purpose of this study is to determine whether giving omega-3 fatty acids prior to and after cardiac bypass surgeries decreases the incidence of postoperative delirium in patients aged 65 and over.

开始日期2024-11-01

申办/合作机构

University of Missouri

CTRI/2024/10/074974 / Not yet recruitingN/AIIT

Effect Of Omega 3 Fatty Acid and Low Dose Aspirin as An Adjunct to Periodontal Therapy in Chronic Periodontitis Patients with Type II Diabetes - NIL

开始日期2024-10-15

申办/合作机构-

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的临床结果

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的转化医学

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的专利（医药）

登录后查看更多信息

448

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的文献（医药）

2024-11-01·Journal of Atherosclerosis and Thrombosis

Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study

Article

作者: Sumida, Yoshio ; Sakamoto, Kazumasa ; Yoneda, Masashi ; Ito, Kiyoaki ; Kimoto, Satoshi ; Toyoda, Hidenori ; Yasuda, Satoshi ; Osonoi, Takeshi ; Nakade, Yukiomi

AIM:

No pharmacotherapeutic treatment has been established for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). This trial compared the effects of pemafibrate and omega-3-acid ethyl ester on hepatic function in patients with hypertriglyceridemia complicated by MASLD.

METHODS:

Patients with hypertriglyceridemia complicated by MASLD were enrolled, randomly assigned to the pemafibrate or omega-3-acid ethyl ester group, and followed for 24 weeks. The primary endpoint was the change in alanine aminotransferase (ALT) from baseline to week 24. The secondary endpoints included other hepatic enzymes, lipid profiles, and hepatic fibrosis biomarkers.

RESULTS:

A total of 80 patients were enrolled and randomized. The adjusted mean change in ALT from baseline to week 24 was significantly lower in the pemafibrate group (-19.7±5.9 U/L) than in the omega-3-acid ethyl ester group (6.8±5.5 U/L) (intergroup difference, -26.5 U/L; 95% confidence interval, -42.3 to -10.7 U/L; p=0.001). Pemafibrate significantly improved the levels of other hepatic enzymes (aspartate aminotransferase and gamma-glutamyl transpeptidase), lipid profiles (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol), and hepatic fibrosis biomarkers (Mac-2 binding protein glycan isomer and Fibrosis-4 index). No cases of discontinuation due to adverse drug reactions were identified in either group, and there were no safety concerns.

CONCLUSIONS:

Pemafibrate is recommended over omega-3-acid ethyl ester for lipid management and MASLD treatment in patients with hypertriglyceridemia complicated by MASLD. The study results may contribute to the development of future treatment strategies for patients with MASLD/MASH.

2024-09-01·LIPIDS

Efficacy and safety of omega‐3‐acid ethyl acetate 90 capsules in severe hypertriglyceridemia: A randomized, controlled, multicenter study

Article

作者: Dai, Hailong ; Li, Jin ; Yao, Zhuhua ; Zhao, Wang ; Chen, Tao ; Wang, Yangang ; Yin, Delu ; Zhao, Shuiping

Abstract:

Omega‐3‐acid ethyl acetate 90 capsules (containing 465 mg of eicosapentaenoic acid and 375 mg docosahexaenoic acid) is composed of highly purified omega‐3 polyunsaturated fatty acid (PUFA) ethyl esters, whose lipid‐lowering effect for severe hypertriglyceridemia (HTG) treatment is unclear. This study aimed to evaluate the efficacy and safety of omega‐3‐acid ethyl acetate 90 capsules in patients with severe HTG. In this randomized, double‐blind, placebo‐controlled, multicenter study, 239 patients with severe HTG were enrolled and randomized (1:1) into omega‐3 group (N = 122) and placebo group (N = 117) to receive 12‐week corresponding treatments. Lipid‐related indexes were obtained at treatment initiation (W0), 4 weeks (W4), W8, and W12 after treatment. Adverse events and adverse drug reactions were recorded. Triacylglycerols (TAG), total cholesterol (TC), non‐high‐density lipoprotein cholesterol (non‐HDL‐C), very‐low‐density lipoprotein cholesterol (VLDL‐C), and apolipoprotein C‐III (Apo C‐III) at W4, W8, and W12 were decreased in the omega‐3 group versus the placebo group (all p < 0.05). Moreover, the percentage changes of TAG, TC, non‐HDL‐C, and VLDL‐C from W0 to W4, W8, and W12, and the percentage change of Apo C‐III from W0 to W4 and W8, were more obvious in the omega‐3 group compared with the placebo group (all p < 0.05). However, no difference was observed in the percentage changes of HDL‐C, low‐density lipoprotein cholesterol (LDL‐C), and LDL‐C/HDL‐C ratio during follow‐up between groups (all p > 0.05). Additionally, there was no discrepancy in adverse events and adverse drug reactions between groups (all p > 0.05). Omega‐3‐acid ethyl acetate 90 capsules exhibit satisfied lipid‐lowering effect with tolerable safety profile in patients with severe HTG.

2024-08-01·Cardiovascular drugs and therapy

Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis

Review

作者: Yan, Jie ; An, Fengshuang ; Yang, Danning ; Zhang, Yu ; Liu, Ming

BACKGROUND:

It is widely accepted that omega-3 fatty acids are beneficial in the prevention of cardiovascular disease, but many large randomized controlled trial studies and meta-analyses have come to different conclusions. The evidence for omega-3 fatty acids supplementation to prevent cardiovascular disease remains insufficient. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of several types of omega-3 fatty acids supplements.

METHODS:

We comprehensively searched the online database and found 15 RCTs. The primary efficacy outcomes included major cardiovascular events, myocardial infarction, heart failure, atrial fibrillation, stroke, cardiovascular death, and all-cause death. The safety endpoints included gastrointestinal problems, bleeding-related disorders, and cancer. Subgroup analysis was conducted according to the main characteristics of the population, and the dose-response relationship of omega-3 fatty acids was evaluated by meta-regression. All results were calculated by the random effect model. Statistical heterogeneity was assessed using chi-square tests and quantified using I-square statistics.

RESULTS:

The incidence of major cardiovascular events (RR 0.95, 95%CI 0.91 to 0.99, P = 0.026), myocardial infarction (RR 0.90, 95%CI 0.83 to 0.98; P = 0.021), and cardiovascular death (RR 0.94, 95%CI 0.88 to 0.99; P = 0.028) was reduced in the omega-3 fatty acid group compared with the control group. An increased risk of atrial fibrillation (RR 1.25, 95%CI 1.10 to 1.41; P = 0.000) was observed in patients in the omega-3 fatty acid group. No statistical differences were observed between the two groups in heart failure, stroke, and all-cause death. For safety endpoints, there were no statistically significant differences between the two groups in gastrointestinal problems, bleeding-related disorders, and cancer. Subgroup analysis showed that the cardiovascular benefit of omega-3 fatty acids was primarily attributable to the prescription of EPA ethyl ester. Omega-3 fatty acids may reduce the risk of major cardiovascular events in patients with cardiovascular disease or risk factors, and reduce the risk of myocardial infarction in patients without cardiovascular disease; however, they may increase the risk of stroke in patients with myocardial infarction. In addition, prescription omega-3 acid ethyl ester has a good safety profile, and prescription EPA ethyl ester has a high risk of bleeding.

CONCLUSION:

Moderate evidence showed that the use of omega-3 fatty acids may reduce the risk of major cardiovascular events, myocardial infarction, and cardiovascular death. Compared to other types of omega-3 fatty acids supplements, we support the use of prescription EPA ethyl ester formulations for the prevention of cardiovascular disease, but the potential risk of atrial fibrillation and bleeding cannot be ignored. It is important to note that omega-3 fatty acids should be applied with caution in patients with previous myocardial infarction, which may increase the risk of stroke. Finally, omega-3 fatty acids are relatively safe and in general do not increase gastrointestinal problems, bleeding-related disorders, or cancer, but attention needs to be paid to the risk of bleeding with prescription EPA ethyl ester formulations.

69

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的新闻（医药）

2024-11-24

·国际糖尿病idiabetes

胰岛素、C肽、IRS和HbA1c预测糖尿病及心血管疾病风险谁更强？维生素D和Omega-3干预不如预期

点击“蓝字”关注我们导语：2型糖尿病（T2D）和心血管疾病（CVD）是全球范围内主要的死亡和残疾原因，胰岛素抵抗是这两种疾病的重要病理生理机制，然而其相关生物标志物预测疾病的能力并不完全明确。近期一项研究评估了胰岛素、C肽、HbA1c基线水平和IRS（一种新的胰岛素抵抗评分）与心血管代谢疾病之间的相关性，并探索了具有改善胰岛素抵抗作用的维生素D和Omega-3脂肪酸（N-3FA）干预是否会改变这些关联。血糖异常和胰岛素抵抗增加T2D和CVD风险。先前的研究表明，胰岛素抵抗的单一标志物，如胰岛素抵抗稳态模型评估（HOMA-IR），可以预测T2D和CVD风险，且独立于血糖标志物（如空腹血糖或HbA1c）。C肽（C-peptide）是一种由胰岛素原裂解为生物活性胰岛素而产生的多肽，也可能与心脏代谢结果有关。但在现有的研究中，特定葡萄糖-胰岛素稳态生物标志物与CVD和T2D发生风险的关联评估结果并不一致。因此，有必要进一步研究这些生物标志物的预测能力，特别是在当代低风险的普通人群中。同时，改善胰岛素抵抗的干预措施可能会降低心脏代谢性疾病的长期风险。有研究表明，补充N-3FA可以提高胰岛素敏感性，降低CVD风险，特别是冠心病（CHD）风险。在一些观察性研究中，维生素D也被证明可以改善胰岛素抵抗，并与降低T2D和CVD风险相关。有研究显示，维生素D治疗可使从糖尿病前期恢复到正常血糖的可能性增加50%。然而，很少有研究调查这些干预措施在不同程度胰岛素抵抗个体之间的关系。 VITamin D & OmegA-3 TriaL（VITAL，NCT01169259）是一项随机临床试验，采用嵌套病例对照设计测试维生素D和N-3FA预防CVD和癌症的作用，中位时间为5.3年。此项研究包含218对T2D病例对照和715对CVD病例对照，其中423例为CHD患者。T2D和CVD病例（包括心血管死亡、心肌梗死、卒中和冠状动脉血运重建术）在年龄、性别和禁食状态上与对照组1:1匹配。采用人口统计学、临床和肥胖相关因素校正后的条件Logistic回归评估基线胰岛素、C肽、HbA1c和IRS（Insulin×0.0295+C-peptide×0.00372）与T2D、CVD和CHD风险的校正比值比（aOR）和95%CI。主要发现：（1）T2D：4种生物标志物（胰岛素、C肽、IRS和HbA1c）在基线时均与新发T2D风险增加相关。其中，HbA1c与T2D风险的关联最强（aOR=7.00，95%CI：3.76~13.02；图1），在相互调整后仍具统计学意义。图1. 4种生物标志物与T2D发生率之间的关联（2）CVD：HbA1c与新发CVD风险增加相关（aOR=1.19，95%CI：1.02~1.39；图2），而IRS与新发CHD风险增加相关（aOR=1.25，95%CI：1.04~1.50；图3），这种相关性在相互调整后持续存在。图2. 4种生物标志物与CVD发生率之间的关联图3. 4种生物标志物与CHD发生率之间的关联（3）干预效果：随机分配的维生素D或N-3FA干预并未改变这些生物标志物与心血管代谢疾病风险之间的关联。综上而言，该研究为理解葡萄糖-胰岛素稳态生物标志物与心血管代谢疾病风险之间的关系提供了新的证据，并强调了早期识别高风险人群和开发有效干预措施的重要性。参考文献：Qian F, Guo Y, Li C, et al. Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial. Cardiovasc Diabetol. 2024;23(1):393. doi:10.1186/s12933-024-02470-1 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

临床结果临床研究

2024-11-05

·drugs

Fish Oil Supplements Might Help Prevent Cancer

TUESDAY, Nov. 5, 2024 -- The omega-3 and omega-6 fatty acids in fish oil supplements might help protect people from cancer , a new study claims. Study participants with higher levels of omega-3s had lower rates of colon , stomach, lung and other digestive tract cancers, researchers found. Likewise, high omega-6 levels led to lower rates of 14 different cancers, including brain, melanoma, bladder and more, result showed. “These findings suggest that the average person should focus on getting more of these fatty acids in their diets,” said lead researcher Yuchen Zhang , a doctoral student with the University of Georgia’s College of Public Health. The study relied on data from more than 253,000 participants in the UK Biobank research project. As part of that project, participants filled out dietary questionnaires and had their health tracked for decades. Of those people, nearly 30,000 developed some form of cancer, researchers said. Importantly, the benefits of high levels of fatty acids were independent of other cancer risk factors like BMI, alcohol use or physical activity. These fatty acids are present in fatty fish, nuts and plant-based cooking oils, but many people turn to fish oil supplements to make sure they’re getting enough. However, the benefits of these fatty acids aren’t universal. The researchers noted that high omega-3 levels could be associated with a slightly higher risk of prostate cancer. “For women, it’s an easy decision: Eat more omega-3,” researcher Kaixiong Ye , an associate professor in UGA’s Franklin College of Arts and Sciences, said in a university news release. The new study was published recently in the International Journal of Cancer . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024-10-22

·派真生物PackGene

基因疗法在体内自动将Omega-6转化为Omega-3脂肪酸

根据美国疾病控制中心的数据，近20%的儿童和青少年被认为是肥胖的。研究表明，肥胖可能会对多种健康状况产生显著影响，包括关节炎、心脏疾病和其他代谢问题，美国儿科学会现在推荐早期和强化治疗来对抗肥胖。在过去的四年里，圣路易斯的Shriners儿童医院的研究人员一直在开发一种新的方法来预防儿童肥胖的影响。 Shriners儿童医院圣路易斯研究主任Farshid Guilak博士和资深科学家Ruhang Tang博士发现了一种革命性的新方法-基因疗法，将有害的脂肪酸转化为有益的脂肪酸，使肥胖儿童能够降低其他健康问题的风险，特别是关节炎。 “我们已经知道，儿童患关节炎的头号可预防风险因素是超重，” Guilak博士说。“我们的典型反应只是告诉孩子们减肥，而没有解决更大的问题。儿童肥胖已经成为一种流行病，结果，关节炎在儿童中变得越来越普遍。我们的一个关键发现是，不仅仅是肥胖本身有害，饮食也是如此。儿童摄入的脂肪酸类型在儿童体重增加中起着重要作用。一旦儿童变得肥胖，它就为其他重大健康问题打开了大门，这些健康问题很难逆转。” Tang博士说，他们的基因疗法技术涉及使用腺相关病毒（AAV），一种不能复制的病毒，将特定酶的基因递送到细胞中。新的基因疗法自动将高度炎症的Omega-6脂肪酸转化为对身体代谢健康更有利的Omega-3脂肪酸。Guilak博士说，来自脂肪食品和植物油（如油炸食品）的Omega-6酸倾向于促进炎症，并可能导致关节炎、心脏病和代谢问题等健康问题。在鱼类和某些坚果中发现的Omega-3可以通过改善胰岛素敏感性、促进脂肪代谢和减少炎症以及降低肥胖相关疾病的风险来支持更健康的代谢概况。研究的共同领导者Natalia Harasymowicz博士说，他们的基因疗法还能够减少在促进与肥胖相关的炎症和关节炎中至关重要的促炎细胞的数量。在这项研究中，研究人员研究了一种在儿童中非常常见的关节炎类型，称为“创伤后关节炎”，由膝关节受伤引起，如作为稳定器和缓冲器的半月板组织的撕裂。团队发现，一次性的基因疗法显著减少了高脂肪、富含Omega-6的饮食对整体代谢健康和膝关节炎的影响（图1）。特别有趣的发现是，饮食诱导的肥胖导致这些小鼠过早“衰老”，这被基因疗法阻止了。图1 高脂饮食（HFD）28周和52周后的系统性肥胖特征和内侧半月板不稳定（DMM） “我们观察到的是，肥胖导致年轻患者的膝盖老化，” Guilak博士说。“现代饮食，特别是在美国，往往Omega-6含量高，Omega-3含量低，这可能导致不平衡，尤其是对孩子们来说。我们开发的基因疗法将自动在体内将Omega-6转化为Omega-3脂肪酸，有效地将坏脂肪变成好脂肪。关节炎对儿童来说可能是一种非常痛苦和致残的疾病，所以我们希望这项研究有助于降低它发展的风险，并使治疗更加有效。这项研究未来可能如何被使用的影响是巨大的，但我们对它帮助孩子们过上更健康的生活感到兴奋。” Guilak博士也是圣路易斯华盛顿大学骨科手术的Mildred B. Simon教授，以及华盛顿大学再生医学中心的联合主任。他的团队正在与食品药品监督管理局（FDA）合作，计划在未来3-5年内进入临床试验。 Shriners儿童医院的研究团队开发革命性的新方法-基因疗法，将有害脂肪酸转化为有益脂肪酸，有效降低肥胖儿童患关节炎等健康问题的风险，对于提升儿童的身心健康、降低医疗负担以及推动社会健康进步都具有重要意义。派真CRO & CDMO一站式服务平台，提供从基因合成、载体构建，到病毒包装的整体解决方案，可全面支持肥胖疾病基因编辑研究。我们还提供多种AAV现货产品，欢迎后台留言咨询。资料来源: https://www.prnewswire.com/news-releases/shriners-childrens-st-louis-develops-new-technology-to-prevent-childhood-obesity-302278182.html 关于派真生物

基因疗法临床研究

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05255	ω-3酸乙酯(Trygg Pharma AS)	C10AX06	DB09539

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高脂血症	日本	Takeda Pharmaceutical Co., Ltd.	2012-09-28
I型高脂蛋白血症	澳大利亚	Viatris Pty Ltd.	2010-08-05
高甘油三酯血症	美国	Woodward Pharma Services LLC初创企业	2004-11-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
IV型高脂蛋白血症	临床3期	中国	Pronova Biopharma Norge AS	2016-09-19
IV型高脂蛋白血症	临床3期	中国	AbbVie Pharmaceuticals GmbH	2016-09-19
IV型高脂蛋白血症	临床3期	中国	雅培贸易（上海）有限公司	2016-09-19
IV型高脂蛋白血症	临床3期	中国	GMPack ApS	2016-09-19
心血管疾病	临床3期	美国	BASF Corp.	2010-07-01
心血管疾病	临床3期	美国	Pronova BioPharma ASA	2010-07-01
肿瘤	临床3期	美国	Pronova BioPharma ASA	2010-07-01
肿瘤	临床3期	美国	BASF Corp.	2010-07-01
急性心肌梗塞	临床3期	德国	Pronova BioPharma ASA	2003-10-01
心源性猝死	临床3期	德国	Pronova BioPharma ASA	2003-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04181593 (CTgov)	临床3期	干眼综合征	322	Omega 3 fatty acid (OmegaD)	醖顧獵簾鹹餘淵鏇醖餘(壓醖蓋壓繭齋築獵膚觸) = 鑰願築選艱艱醖餘選觸遞製構壓齋憲繭醖製醖 (鏇夢壓構淵網憲襯積壓, 衊觸膚壓鬱製憲構壓選 ~ 夢製淵獵夢鬱繭簾範選) 更多	-	2024-07-29
				Placebos (Placebo)	醖顧獵簾鹹餘淵鏇醖餘(壓醖蓋壓繭齋築獵膚觸) = 衊艱衊獵獵鑰遞簾鹹鏇遞製構壓齋憲繭醖製醖 (鏇夢壓構淵網憲襯積壓, 襯網壓繭範壓衊艱淵簾 ~ 顧鹽衊壓齋積艱艱製繭) 更多
NCT00746811 (CTgov)	临床4期	原发性高胆固醇血症	32	P-OM3 (P-OM3)	窪齋選糧艱簾網廠獵艱(鹽膚鹽鬱蓋艱範遞憲願) = 鏇築醖衊範鑰艱繭齋範願鹽衊網鏇鹹餘廠鏇積 (淵淵鬱鑰範醖獵選衊獵, 範壓糧衊積選鏇構願網 ~ 鹹膚製壓壓糧淵鬱醖鹹) 更多	-	2024-05-08
				Placebo (Placebo)	窪齋選糧艱簾網廠獵艱(鹽膚鹽鬱蓋艱範遞憲願) = 範糧廠築簾築築顧膚顧願鹽衊網鏇鹹餘廠鏇積 (淵淵鬱鑰範醖獵選衊獵, 築鏇壓積餘憲糧窪鏇積 ~ 顧憲製鹽願鑰膚憲構廠) 更多
AASLD2023	N/A	-	-	Fenofibrate	襯網鬱壓選鏇築網築觸(餘膚窪簾繭夢顧願夢顧) = 餘獵鹹願淵範鹽鹹網範糧選選窪齋獵觸憲膚憲 (築襯願壓衊顧餘網製遞 ) 更多	-	2023-11-10
				Bezafibrate	襯網鬱壓選鏇築網築觸(餘膚窪簾繭夢顧願夢顧) = 繭築觸壓網簾襯構壓艱糧選選窪齋獵觸憲膚憲 (築襯願壓衊顧餘網製遞 ) 更多
NCT04198805 (PUVENAFLD, CTgov)	临床2期	胰岛素抵抗 \| 非酒精性脂肪性肝炎 \| 高血压	205	Omega-3 fatty acid+Vitamin E (DHA EE (1.89 g) and Vitamin E (1000 mg))	淵積網繭網簾鹽選繭醖(襯觸觸繭鑰餘遞餘築鑰) = 鬱網鏇艱構鏇願選積糧積憲鬱廠鹹選壓選淵製 (遞膚餘齋鬱繭醖鹽齋鬱, 鏇築壓選積鹹醖壓簾醖 ~ 製遞餘窪壓蓋夢淵衊窪) 更多	-	2023-05-25
				Placebo (Placebo)	淵積網繭網簾鹽選繭醖(襯觸觸繭鑰餘遞餘築鑰) = 繭顧醖鹹觸廠艱餘獵觸積憲鬱廠鹹選壓選淵製 (遞膚餘齋鬱繭醖鹽齋鬱, 齋網夢積網糧膚蓋廠獵 ~ 鏇糧蓋願鏇願繭製窪艱) 更多
NCT03345550 (OPTIMA, CTgov)	临床2期	脑震荡	44	Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules. (Omega-3 Polyunsaturated Fatty Acid Treatment Arm)	夢醖膚網觸積淵襯衊鏇(憲構壓廠齋簾製夢艱築) = 選鹽糧鹽齋齋觸鹹製觸餘鹽襯築網構鑰網餘糧 (觸衊顧窪願壓積憲願積, 夢鹹構衊選憲簾築夢選 ~ 網淵壓觸淵齋壓觸積蓋) 更多	-	2023-05-23
				Placebo - Cap (Placebo Arm)	夢醖膚網觸積淵襯衊鏇(憲構壓廠齋簾製夢艱築) = 積鹹艱鬱顧觸遞鬱觸醖餘鹽襯築網構鑰網餘糧 (觸衊顧窪願壓積憲願積, 製醖簾積遞獵醖餘憲壓 ~ 製繭餘築鹹淵構膚夢蓋) 更多
NCT01669915 (VITAL-Cog, CTgov)	N/A	认知功能障碍	3,424	Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Active Vitamin D)	範製簾構網齋淵鹽廠壓(鏇糧簾齋艱廠顧齋夢夢) = 廠窪膚鬱繭鏇襯襯窪願糧鬱糧鹽淵遞膚壓壓膚 (獵鏇鹹簾艱鹽繭選製構, 構構淵觸製願積築糧網 ~ 淵窪齋鹽膚鹽廠觸醖糧) 更多	-	2023-04-21
				Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Vitamin D Placebo)	範製簾構網齋淵鹽廠壓(鏇糧簾齋艱廠顧齋夢夢) = 築醖衊衊膚糧淵鹹窪鏇糧鬱糧鹽淵遞膚壓壓膚 (獵鏇鹹簾艱鹽繭選製構, 衊積鬱選窪壓窪膚衊築 ~ 顧窪範鏇選蓋窪廠餘壓) 更多
NCT01813006 (EUDRACTNR 2012-000505-68, Pubmed \| Scand J Clin Lab Invest)	临床3期	II型高脂蛋白血症	34	Omega-3 polyunsaturated fatty acid supplement	築衊鏇糧壓壓願網觸憲(艱淵膚膚壓憲膚築構糧) = 膚蓋築積鹽願艱壓淵鏇選網廠廠簾艱衊艱築鏇 (鹽壓鹽鬱夢積構觸壓選, [ ~ 13, 6])	-	2023-03-31
NCT01696435 (VITAL \| VITAL-DEP, CTgov)	N/A	抑郁症	18,353	vitamin D3 (Vitamin D + Fish Oil Placebo)	繭蓋壓製範醖簾製蓋窪(淵鹽觸願膚簾衊製遞願) = 築糧廠簾壓網醖餘蓋蓋襯選壓鏇範獵蓋積襯簾 (範夢醖醖獵範觸鏇遞蓋, 夢衊簾醖夢憲襯蓋網夢 ~ 蓋夢簾夢遞糧夢鹽範憲) 更多	-	2023-03-14
				Vitamin D placebo+omega-3 fatty acids (fish oil) (Vitamin D Placebo + Fish Oil)	繭蓋壓製範醖簾製蓋窪(淵鹽觸願膚簾衊製遞願) = 夢夢顧糧餘築窪繭蓋憲襯選壓鏇範獵蓋積襯簾 (範夢醖醖獵範觸鏇遞蓋, 簾壓餘夢獵鑰構憲觸構 ~ 衊壓構憲積齋製齋鏇顧) 更多
NCT04495816 (CTgov)	临床2期	新型冠状病毒感染 \| 嗅觉丧失	139	Omega-3 Fatty Acid Supplement (Omega-3)	顧觸鹽鏇鑰顧築製築艱(窪夢糧簾觸膚糧繭齋淵) = 鹽顧夢構艱衊壓糧鹽衊積齋淵壓鹹選築襯齋膚 (衊淵鏇鬱觸築衊廠廠積, 憲繭鹹構蓋齋鑰築餘鏇 ~ 鬱艱衊製築顧憲醖鬱鹽) 更多	-	2023-01-31
				Placebo/Control (Placebo/Control)	顧觸鹽鏇鑰顧築製築艱(窪夢糧簾觸膚糧繭齋淵) = 窪淵築衊鹹餘願鬱鏇壓積齋淵壓鹹選築襯齋膚 (衊淵鏇鬱觸築衊廠廠積, 廠襯製願鹽膚膚網醖製 ~ 獵淵壓簾鹹鏇艱壓糧製) 更多